Prolia Scientific Support

Prolia has been studied in close to 10,000 postmenopausal women enrolled in clinical trials of up to 10 years in duration (4,886 Prolia vs. 4,886 comparator arms).1

freedom study

Green arrow pointing down


The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months) study is Prolia’s pivotal phase III, randomized, double-blind, controlled study completed with 7,808 postmenopausal women.1,2

The safety profile and efficacy of Prolia were evaluated in the FREEDOM trial and the results were published in the New England Journal of Medicine. FREEDOM’s primary endpoint was the incidence of new vertebral fracture over a period of 36 months. Secondary endpoints included the time to first nonvertebral fracture and time to first hip fracture.2

7,808 women between the ages of 60 and 91 years old with BMD T scores less than -2.5 and not less than -4.0 at the lumbar spine or total hip were enrolled in FREEDOM and randomized to receive either Prolia or placebo.1*

FREEDOM Trial Infographic

Key Findings

The key finding in the 3-year study was that patients taking Prolia had a significant reduction in the risk of new fracture at all measured sites (vertebral, hip, nonvertebral) compared with those taking placebo.

In the long-term, open-label extension, among 2,343 women who received Prolia in FREEDOM and continued on therapy (years 4 through 10 of Prolia treatment), 1,343 (57.3%) completed 10 years. Prolia treatment maintained a low incidence of new vertebral fractures in years 4 through 10 (7.0% had at least one new vertebral fracture).1

Spine Icon

New vertebral fractures



Vertebral Fracture Chart
Hip Fracture Icon

Hip fractures



Hip Fracture Chart
Nonvertebral Fracture Risk Reduction Icon

Non-vertebral fractures



Nonvertebral Fracture Chart

In the long-term, open-label extension, Prolia treatment also continued to increase BMD from extension baseline at the lumbar spine (10.8%; n=1,264), total hip (3.4%; n=1,232), and femoral neck (3.8%; n=1,232) over years 4 through 10. Percent increase in BMD from the original FREEDOM study baseline (i.e. after 10 years of treatment) in the long-term group was 21.7% at the lumbar spine, 9.2% at the total hip, and 9.0% at the femoral neck.

Additional Resources

Freedom Icon
FREEDOM Clinical Trial

Access the FREEDOM clinical trial in the virtual library.

FREEDOM TrialArrow Image
Safety logo

You are now leaving the website.

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.

Do you want to link to our other external sites and leave

You are now leaving the website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.


Do you want to link to another Amgen Canada site?

Yes, leave  

You are now leaving the website. Please note that these links are being provided as a convenience and for informational purposes only.